Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lacosamide→

Lacosamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
175481-36-4
Molecular formula
C13H18N2O3
Molecular weight
250.29 g/mol
Drug class
Decreased Central Nervous System Disorganized Electrical Activity
Mechanism of action
Sodium Channel Interactions
Indications / reported uses
  • Epilepsies, Partial
  • Epilepsy, Tonic-Clonic
  • Lennox Gastaut Syndrome
  • partial-onset seizures in patients 4 years of age and older
  • partial-onset seizures in patients 17 years of age and older

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lacosamide Environmental Risk Assessment (ERA) (the Lacosamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.